Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Stasi

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
British Journal of Haematology|February 13, 2010
The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemiaGiovanni Del Poeta, Emanuele Ammatuna, Serena Lavorgna, et al.
Blood|March 12, 2005
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 studySergio Amadori, Stefan Suciu, Ulrich Jehn, et al.
British Journal of Haematology|November 16, 2011
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)Sergio Amadori, Roberto Stasi, Alberto M Martelli, et al.
Blood|May 9, 2012
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopeniaVivek L Patel, Matthieu Mahévas, Soo Y Lee, et al.
Blood|January 31, 2013
Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working GroupFrancesco Rodeghiero, Marc Michel, Terry Gernsheimer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10Franco Mandelli, Marco Vignetti, Stefan Suciu, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|July 18, 2002
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumorsAntonio Bruno, Tommaso Caravita, Gaspare Adorno, et al.
Blood|November 14, 2008
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupFrancesco Rodeghiero, Roberto Stasi, Terry Gernsheimer, et al.
Blood|October 23, 2009
International consensus report on the investigation and management of primary immune thrombocytopeniaDrew Provan, Roberto Stasi, Adrian C Newland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17)Sergio Amadori, Stefan Suciu, Roberto Stasi, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
British Journal of Haematology|February 13, 2010
The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemiaGiovanni Del Poeta, Emanuele Ammatuna, Serena Lavorgna, et al.
Blood|March 12, 2005
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 studySergio Amadori, Stefan Suciu, Ulrich Jehn, et al.
British Journal of Haematology|November 16, 2011
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)Sergio Amadori, Roberto Stasi, Alberto M Martelli, et al.
Blood|May 9, 2012
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopeniaVivek L Patel, Matthieu Mahévas, Soo Y Lee, et al.
Blood|January 31, 2013
Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working GroupFrancesco Rodeghiero, Marc Michel, Terry Gernsheimer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10Franco Mandelli, Marco Vignetti, Stefan Suciu, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|July 18, 2002
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumorsAntonio Bruno, Tommaso Caravita, Gaspare Adorno, et al.
Blood|November 14, 2008
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupFrancesco Rodeghiero, Roberto Stasi, Terry Gernsheimer, et al.
Blood|October 23, 2009
International consensus report on the investigation and management of primary immune thrombocytopeniaDrew Provan, Roberto Stasi, Adrian C Newland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17)Sergio Amadori, Stefan Suciu, Roberto Stasi, et al.
Pageof 9